Articles tagged with Chimeric Antigen Receptor Therapy
A study published in Blood Advances found liso-cel to be a cost-effective treatment for r/r DLBCL, with a lower societal ICER of $68,212 per QALY. The treatment offered improved quality-adjusted life years and reduced lost productivity costs.
A phase 1 clinical trial demonstrates the efficacy of third-generation anti-CD19 CAR T-cells in treating relapsed or refractory B-cell non-Hodgkin lymphomas without causing neurotoxicity. The study also shows a robust response rate of 52% and improved safety profile compared to previous CAR T-cell therapies.
Researchers developed a technology to rapidly screen genetic edits in immune cells, identifying a new combination that improves their effectiveness against cancers. By combining multiple genes into long DNA stretches and testing thousands of combinations, scientists discovered that different CARs can be optimized by different factors.
A new EIC project, CAR T-REX, will develop novel, scalable CAR T cell therapies for the treatment of solid tumors. The consortium aims to overcome current limitations, including high manufacturing costs and limited efficacy, through a novel paradigm for generating improved CAR T cells.
A new study finds no significant difference in overall survival or complete remission rates between children and young adults with different levels of poverty exposure, regardless of their neighborhood opportunity. CAR T-cell therapy is equally effective for those from disadvantaged households as it is for those from more socioeconomic...
Researchers produce large quantities of powerful cancer-fighting iNKT cells using stem cell engineering and organoid technology, offering a potential solution for mass-producing an off-the-shelf immune cell therapy. The therapy, which uses hematopoietic stem cell-engineered iNKT cells, has been shown to be effective in killing multiple...